MUTYH

protein-coding

mutY DNA glycosylase, the group of DNA glycosylases

Gene summary

This gene encodes a DNA glycosylase involved in oxidative DNA damage repair. The enzyme excises adenine bases from the DNA backbone at sites where adenine is inappropriately paired with guanine, cytosine, or 8-oxo-7,8-dihydroguanine, a major oxidatively damaged DNA lesion. The protein is localized to the nucleus and mitochondria. This gene product is thought to play a role in signaling apoptosis by the introduction of single-strand breaks following oxidative damage. Mutations in this gene result in heritable predisposition to colorectal cancer, termed MUTYH-associated polyposis (MAP). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2017]

MANE transcript

NM_001048174.2

Inheritance

AR, AD

ClinVar variants

P:499U:1770B:1043

Top phenotype

Familial adenomatous polyposis, 2; Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas

gnomAD constraint

pLI —, LoF o/e 0.88

Max pathogenic AF

—

Genomic locus

chr1:45,329,163-45,340,893

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~11.7 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

hereditary breast carcinomaNO_KNOWN

Inheritance Pattern: AR

Disease ID:MONDO:0016419

Submitter: ClinGen

MUTYH is a DNA glycosylase involved in the base excision DNA repair pathway. Biallelic and monoallelic variants in *MUTYH* were linked to multiple types of cancer and/or tumor, including hereditary breast cancer, familial ovarian cancer, familial adenomatous polyposis and colorectal cancer. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we have split these associations into different curations due to phenotypic differences and/or inheritance mechanism. Therefore, this curation solely focuses on autosomal recessive hereditary breast cancer. **Summary of Case-Control Data: 0 point** To date, this gene-disease relationship has been studied in one large case-control study at the aggregate variant level in 2017 (PMID: 35172496). This study screened breast cancer cases from commercial laboratories and did not find significant association of biallelic variants in *MUTYH* with breast cancer. **Overall Summary:** In summary, given that the only one case-control study showed no increased risk for breast cancer in biallelic *MUTYH* variant carriers, and no experimental data support this gene-disease relationship, the Hereditary Cancer GCEP has disputed this gene-disease association. More evidence is needed to either support or entirely refute the role *MUTYH* plays in autosomal recessive hereditary breast cancer. This gene-disease pair was originally evaluated as no known disease relationship by the Breast/Ovarian Cancer GCEP on 05/24/2017. This re-curation was approved by the ClinGen Hereditary Diseases GCEP on 06/23/2023 (SOP Version 9).

familial adenomatous polyposis 2DEFINITIVE

Inheritance Pattern: AR

Disease ID:MONDO:0012041

Submitter: ClinGen

MUTYH was first reported in relation to MUTYH-related attenuated familial adenomatous polyposis , also known as MUTYH-Associated Polyposis (MAP), by Jones S, et al (PMID: 12393807) and Al-Tassan N, et al., (PMID: 11818965) in 2002. MUTYH has been noted to be associated with both autosomal recessive and autosomal dominant MUTYH-related attenuated familial adenomatous polyposis. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, this curation focuses solely on autosomal recessive MUTYH-related attenuated familial adenomatous polyposis (MONDO:0012041) due to the difference in inheritance pattern and phenotype differences. This autosomal recessive condition causes an increased risk of colorectal adenomas and colon cancer (see Nielsen et al. PMID:23035301 for clinical phenotype). At least 7 cases from Jones et al contributed homozygous truncating or missense, or compound heterozygous alleles, and Al-Tassan reported on a larger pedigree with three siblings segregating biallelic alleles consistent with recessive inheritance. A case control study by Cleary et al (PMID: 19245865, 2009) identified 27 homozygous or compound heterozygous cases (with 1 control subject carrying a homozygous variant) through a large case-control study. Through cases, segregation and case-control, the maximum score for genetic evidence has been reached (12 points) although more evidence is available in the literature. This gene-disease association is also supported by experimental evidence (5.5 points) including MUTYH colonic tissue expression (PMID:22876359, PMID:25613900), a mouse model developing colonic polyps (PMID: 17638869), biochemical function of MUTYH in base excision repair deficiency (PMID: 15199168), and MUTYH knockout in mouse ES cells disrupting DNA glycosylase activity (and base excision repair) (PMID: 12917422). In summary, MUTYH recessive variants are definitively associated (17.5 points) with MUTYH-related attenuated familial adenomatous polyposis (MONDO:0012041), also known as MUTYH-Associated Polyposis (MAP). This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.

familial adenomatous polyposis 2STRONG

Inheritance Pattern: AR

Disease ID:MONDO:0012041

Submitter: Labcorp Genetics (formerly Invitae)

colorectal cancerNO_KNOWN

Inheritance Pattern: AD

Disease ID:MONDO:0005575

Submitter: ClinGen

MUTYH is a DNA glycosylase involved in the base excision DNA repair pathway. Monoallelic germline MUTYH variants were first reported in relation to colorectal cancer (MONDO:0005575) in 2004 (Croitoru et al., PMID: 15523092). Of note, bi-allelic variants in MUTYH are associated with autosomal recessive familial adenomatous polyposis 2 (MONDO:0012041). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we have split the association of MUTYH and recessive familial adenomatous polyposis 2 in another curation due to phenotypic differences and inheritance mechanism. **Summary of Case-Control Data: 3 points** Given the potential for phenocopies due to the high population incidence of colorectal cancer, case-level reports were not scored for this curation. Instead, case-control studies and cohort studies were considered the strongest form of genetic evidence. In total, four case-control studies and one cohort study were included in this curation. The case-control studies included meta-analyses, aggregate variant analyses and single variant analyses. Some studies suggested a slightly increased risk for colorectal cancer in monoallelic MUTYH variant carriers compared to controls (PMID: 21063410, 24444654, 23946381) and other studies suggested no increased risk for colorectal cancer in monoallelic MUTYH variant carriers (29478780, 33309985). **Summary of Experimental Data: 3 points** There is experimental evidence showing a role for MUTYH in DNA repair (base excision and mismatch repair) pathways, including a null mouse model (PMID: 17638869) which is also a model for the recessive disorder, and in vitro functional studies (PMIDs: 24569162, 15199168, 11801590). **Overall Summary** In summary, given that case-control studies show either a slightly increased risk, or no increased risk for colorectal cancer in monoallelic MUTYH variant carriers, and limited experimental data support this gene-disease relationship, the Hereditary Cancer GCEP has disputed this gene-disease association. More evidence is needed to either support or entirely refute the role MUTYH plays in autosomal dominant colorectal cancer. This gene-disease pair was originally evaluated (in relation to autosomal dominant familial adenomatous polyposis 2) as moderate by the Colon Cancer GCEP on 10/09/2017. This re-curation was approved by the ClinGen Hereditary Diseases GCEP on 03/24/2023 (SOP Version 9).

hereditary breast carcinomaNO_KNOWN

Inheritance Pattern: AD

Disease ID:MONDO:0016419

Submitter: ClinGen

MUTYH is a DNA glycosylase involved in the base excision DNA repair pathway. Biallelic and monoallelic variants in *MUTYH* were linked to multiple types of cancer and/or tumor, including hereditary breast cancer, familial ovarian cancer, familial adenomatous polyposis and colorectal cancer. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we have split these associations into different curations due to phenotypic differences and/or inheritance mechanism. Therefore, this curation solely focuses on autosomal dominant hereditary breast cancer and given the frequency of variants and the cancer phenotype the curation focuses on case-control studies. **Summary of Case-Control Data: 0 point** This gene-disease relationship has been studied in at least 4 case-control studies at the aggregate or single variant level. In 2021, a large case-control study [BCAC, with more than 48 thousand cases and controls (PMID: 33471991)] did not identify a significant association of aggregate loss of function (LOF) variants in *MUTYH* and autosomal dominant breast cancer. Likewise, another large case-control study published in 2022 did not find significant association with autosomal dominant breast cancer (PMID: 34981295). In addition, PMIDs: 22297469, 27466510 showed no significant association of monoallelic *MUTYH* variants with breast cancer although with a small population. **Overall Summary:** In summary, given the lack of significant association in large breast cancer case-control studies to date, there is convincing evidence refuting the association between *MUTYH* and autosomal dominant hereditary breast cancer. This gene-disease pair was originally evaluated as no known disease relationship by the Breast/Ovarian Cancer GCEP on 05/25/2017. This re-curation was approved by the ClinGen Hereditary Diseases GCEP on 06/23/2023 (SOP Version 9).

familial adenomatous polyposis 2SUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0012041

Submitter: Orphanet

familial adenomatous polyposis 2STRONG

Inheritance Pattern: AR

Disease ID:MONDO:0012041

Submitter: Genomics England PanelApp

familial ovarian cancerNO_KNOWN

Inheritance Pattern: AD

Disease ID:MONDO:0016248

Submitter: ClinGen

MUTYH is a DNA glycosylase involved in the base excision DNA repair pathway. Biallelic and monoallelic variants in *MUTYH* were linked to multiple types of cancer and/or tumor, including hereditary breast cancer, familial ovarian cancer, familial adenomatous polyposis and colorectal cancer. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we have split these associations into different curations due to phenotypic differences and/or inheritance mechanism . Therefore, this curation solely focuses on autosomal dominant familial ovarian cancer. **Summary of Case-Control Data: 0 point** To date, this gene-disease relationship has been studied in one cohort studies at the aggregate variant level. This cohort studies suggested no increased risk for ovarian cancer in monoallelic *MUTYH* variant carriers compared to controls (PMID: 27194394). **Overall Summary** In summary, given that the only one cohort study showed no increased risk for ovarian cancer in monoallelic *MUTYH* variant carriers, and no experimental data support this gene-disease relationship, the Hereditary Cancer GCEP has disputed this gene-disease association. More evidence is needed to either support or entirely refute the role *MUTYH* plays in autosomal dominant ovarian cancer. This gene-disease pair was originally evaluated as limited by the Breast/Ovarian Cancer GCEP on 11/29/2017. This re-curation was approved by the ClinGen Hereditary Diseases GCEP on 06/23/2023 (SOP Version 9).

familial adenomatous polyposis 2DEFINITIVE

Inheritance Pattern: AR

Disease ID:MONDO:0012041

Submitter: G2P

familial ovarian cancerNO_KNOWN

Inheritance Pattern: AR

Disease ID:MONDO:0016248

Submitter: ClinGen

MUTYH is a DNA glycosylase involved in the base excision DNA repair pathway. Biallelic and monoallelic variants in *MUTYH* were linked to multiple types of cancer and/or tumor, including hereditary breast cancer, familial ovarian cancer, familial adenomatous polyposis and colorectal cancer. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we have split these associations into different curations due to phenotypic differences and/or inheritance mechanism. Therefore, this curation solely focuses on autosomal recessive familial ovarian cancer. **Summary of Case-Control Data: 0 point:** This gene-disease relationship has been studied in at least 3 case-control or cohort studies at the aggregate variant level. Two cohort studies suggested an increased risk for ovarian cancer in biallelic *MUTYH* variant carriers compared to controls (PMID: 19732775, 27194394). However, the cohort population in these two studies may include the probands with colorectal cancer and polyposis in addition to ovarian cancer; therefore, the association of *MUTYH* and autosomal recessive ovarian cancer cannot be specified. Another case-control study suggested no increased risk for ovarian cancer in biallelic *MUTYH* variant carriers (PMID: 35172496). **Overall Summary:** In summary, given that case-control studies show inconclusive results or no increased risk for ovarian cancer in biallelic *MUTYH* variant carriers, and no experimental data support this gene-disease relationship, the Hereditary Cancer GCEP has disputed this gene-disease association. More evidence is needed to either support or entirely refute the role *MUTYH* plays in autosomal recessive ovarian cancer. This gene-disease pair was originally evaluated as limited by the Breast/Ovarian Cancer GCEP on 11/29/2017. This re-curation was approved by the ClinGen Hereditary Diseases GCEP on 06/23/2023 (SOP Version 9).

Clinical Genomic Database (CGD)

Familial adenomatous polyposis, 2; Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomasAR

Manifestation: Dermatologic; Oncologic

Intervention: Oncologic

Rationale: Individuals may present with colonic neoplasia, and regular surveillance for neoplasms may allow early treatment of tumors, which may improve outcomes; In some individuals, additional surgical measures such as total colectomy with ileorectal anastomosis, may be indicated in addition to surveillance for neoplasms; In addition to colorectal neoplasms, individuals are at high risk for a number of other cancer types (including breast cancer), and awareness may allow early diagnosis and treatment

Comments: Variants may also be inolved in susceptibility to other types of malignancies

Refs: 11818965; 12393807; 12853198; 12606733; 15690400; 21061173; 21063410; 21171015; 21696383; 22371070; 22658618; 22744763; 22851115; 22865608Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to MUTYH variants in ClinVar

47 Conditions Cataloged
Hereditary cancer-predisposing syndromeTotal: 3193
Familial adenomatous polyposis 2Total: 2346
not providedTotal: 536
not specifiedTotal: 353
MUTYH-related disorderTotal: 126
Gastric cancerTotal: 126
Carcinoma of colonTotal: 44
PilomatrixomaTotal: 14

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_001048174.2. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
1
clinvar
3
clinvar
15
clinvar
562
clinvar
10
clinvar
591
missense
5
clinvar
131
clinvar
1729
clinvar
389
clinvar
79
clinvar
2333
nonsense
53
clinvar
34
clinvar
5
clinvar
92
start loss
1
clinvar
5
clinvar
6
frameshift
100
clinvar
76
clinvar
7
clinvar
183
splice donor/acceptor (+/-2bp)
10
clinvar
85
clinvar
9
clinvar
3
clinvar
107
Total1693301770954893312

Highest pathogenic variant AF is 0.0047300453

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 253 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_001048174.2RefSeqNP_001041639.115MANE Select
ENST00000456914.7EnsemblENSP00000407590.215MANE Select
NM_001048171.2RefSeqNP_001041636.215Standard
NM_001048172.2RefSeqNP_001041637.115Standard

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Base excision repair - Homo sapiens (human)
  • DNA Repair
  • Recognition and association of DNA glycosylase with site containing an affected purine
  • Cleavage of the damaged purine
  • Depurination

Biological Process

  • DNA repair
  • base-excision repair
  • mismatch repair
  • depurination

Molecular Function

  • purine-specific mismatch base pair DNA N-glycosylase activity
  • protein binding
  • DNA N-glycosylase activity
  • oxidized purine DNA binding
  • MutLalpha complex binding

Cellular Component

  • nucleus
  • nucleoplasm
  • mitochondrion

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000372098
Coding exons
16
Length
11308
Individuals with no LoFs
125272
Homozygous LoFs
8
Heterozygous LoFs
468
Defined
125748
p
0.00189
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense-0.2073223121.030.00002053474
Missense (PolyPhen)9692.4221.03871023
Synonymous-0.1271261241.010.000007241149
Loss of Function0.6623034.20.8780.00000180352

Population LoF Frequency

PopulationCAFp-valueStatus
African0.000310.00031rare
Latino/Admixed American0.00150.0015notable
Ashkenazi Jewish0.0000990.000099rare
East Asian0.0160.016notable
Finnish00.0absent
European (Non-Finnish)0.000490.00048rare
South Asian0.00230.0022notable
Other0.000660.00065rare

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Involved in oxidative DNA damage repair. Initiates repair of A*oxoG to C*G by removing the inappropriately paired adenine base from the DNA backbone. Possesses both adenine and 2- OH-A DNA glycosylase activities. {ECO:0000269|PubMed:10684930, ECO:0000269|PubMed:20418187, ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570, ECO:0000269|PubMed:26694661}.;
Disease
DISEASE: Familial adenomatous polyposis 2 (FAP2) [MIM:608456]: A condition characterized by the development of multiple colorectal adenomatous polyps, benign neoplasms derived from glandular epithelium. Some affected individuals may develop colorectal carcinoma. {ECO:0000269|PubMed:11818965, ECO:0000269|PubMed:12606733, ECO:0000269|PubMed:12853198, ECO:0000269|PubMed:15366000, ECO:0000269|PubMed:16134147, ECO:0000269|PubMed:16287072, ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:16941501, ECO:0000269|PubMed:18091433, ECO:0000269|PubMed:18515411, ECO:0000269|PubMed:19953527, ECO:0000269|PubMed:20418187, ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570, ECO:0000269|PubMed:26694661}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. {ECO:0000269|PubMed:15273732, ECO:0000269|PubMed:25820570}. Note=The gene represented in this entry may be involved in disease pathogenesis. Somatic mutations contribute to the development of a sub-set of sporadic gastric cancers in carriers of Helicobacter pylori (PubMed:15273732). {ECO:0000269|PubMed:15273732}.;

Recessive Scores

pRec
0.291

Intolerance Scores

LoFtool
0.0243
RVIS EVS
0.11
RVIS percentile EVS
62.1

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
S
Essential (gene trap)
N
Indispensability pred.
E
Indispensability score
0.684

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.